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Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. 
Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to 
maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs 
have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are cur-
rently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD 
and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early 
and individualize treatment of NAFLD in patients with diabetes.
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INTRODUCTION
Epidemiological evidence suggests a strong bidirectional rela-
tionship between type 2 diabetes mellitus (T2DM), including 
its risks, and the severity of nonalcoholic fatty liver disease 
(NAFLD), progression to nonalcoholic steatohepatitis (NASH), 
and advanced fibrosis, independent of liver enzymes [1,2]. 
Furthermore, the coexistence of T2DM and NAFLD results in 
an unfavorable metabolic profile and increased cardiovascular 
risk [2-4], which makes lifestyle correction fundamental in all 
patients regardless of diabetes. Based on epidemiologic and 
clinical trial data, management of T2DM patients with NAFLD 
should aim to reduce risk factors associated with the high car-
diovascular risk of these patients [3], decrease hepatic fat accu-
mulation, and delay the progression of inflammation and fi-
brosis [5,6].
WEIGHT REDUCTION
It is well established that weight loss in overweight or obese in-
dividuals with T2DM, either by lifestyle modification or bar-
iatric surgery, results in significant improvement or resolution 
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of T2DM and its comorbidities such as hypertension and hy-
perlipidemia [3,7,8]. In addition, weight reduction has been 
associated with a reduction in intrahepatic fat content and 
normalization of aminotransferase levels [9]. Even a relatively 
small amount of weight loss can reduce liver fat and improve 
hepatic insulin resistance. Petersen et al. [10] demonstrated 
that moderate weight loss (86 kg before weight loss, 78 kg after 
weight loss) in patients with poorly controlled T2DM could 
normalize fasting hyperglycemia by mobilizing the relatively 
small pool of intrahepatic lipids, which reversed hepatic insu-
lin resistance and normalized rates of basal glucose produc-
tion, independent of any changes in insulin-stimulated periph-
eral glucose metabolism. These results are applicable not only 
to the obese adult population, but also the non-obese adult 
population. In both nonobese and obese subjects with NAFLD 
[11,12], lifestyle intervention involving the combination of 
diet, exercise, and behavior modification with a goal of 7% to 
10% weight reduction results in more weight loss, more fre-
quent resolution of NASH, and a borderline higher reduction 
in NAFLD activity score (NAS). However, in a 12-month un-
controlled study of subjects participating in a diet and exercise 
program, 15 subjects (out of 23 enrolled) who completed the 
study failed to lose weight and there was no change in their liv-
er histology based on liver biopsies at the start and end of the 
study [13].
A systematic review of 23 studies of adult populations with 
NAFLD to determine the effects of lifestyle interventions such 
as dietary modifications, physical activity, and/or exercise on 
hepatic indicators of steatosis, inflammation, and fibrosis, and 
glucose control/insulin sensitivity revealed that reductions in 
liver fat and/or liver aminotransferase concentrations were the 
most strongly correlated with weight loss [14]. Of the five stud-
ies that investigated changes in histopathology, all showed a 
trend towards reduction in inflammation, and this was statisti-
cally significant in two of the studies. The majority of studies 
also reported improvements in glucose control and insulin 
sensitivity following intervention. These studies concluded that 
diet-based lifestyle modifications leading to weight reduction 
and/or increased physical activity consistently reduced liver fat 
and improved glucose control/insulin sensitivity [14]. Howev-
er, it should be borne in mind that sustainable maintenance of 
weight loss with lifestyle interventions for long-term periods 
was achieved in only 3% to 6% of subjects [9,15]. Furthermore, 
little is known about the effects of lifestyle intervention on liver 
histology after 1 year, or what the best strategy to maintain 
weight loss over time is. 
Another systematic review and meta-analysis of 15 studies 
(766 paired liver biopsies) that examined the effects of weight 
loss after bariatric surgical procedures on NAFLD reported a 
mean reduction in body mass index (BMI) after bariatric sur-
gery ranging from 19.1% to 41.8%. The pooled proportion of 
patients with improvement or resolution of steatosis was 
91.6%, followed by 81.3% for steatohepatitis and 65.5% for fi-
brosis. The proportion of patients with complete resolution of 
NASH was 69.5% [16]. 
Magnitude of weight reduction
In adult populations with NAFLD, a greater degree of weight 
loss, induced by either lifestyle modifications or bariatric sur-
gery, is associated with greater improvement in histologic fea-
tures. In this context, the amount of reduction in body weight 
is a determinant of histologic improvement of liver injury and 
fibrosis [9]. Among the few well-controlled studies with paired 
liver biopsies, an improvement in hepatic steatosis and necro-
inflammation was observed in patients with ≥7% weight re-
duction over 48 weeks based on a moderate-intensity hypoca-
loric diet and exercise program (200 min/wk) [11]. A similar 
paired biopsy study in 261 patients who underwent a 12-month 
intervention with a hypocaloric diet combined with walking 
200 min/wk reported similar benefits, although this study was 
not controlled. In this study, a dose-response relationship was 
clear among weight loss and all NASH-related histologic pa-
rameters, with the greatest reduction observed in those with 
the greatest weight loss. The highest rates of NAS reduction, 
steatohepatitis resolution, and fibrosis regression occurred in 
patients with ≥10% weight loss [17]. In patients with poorly 
controlled T2DM, a relatively modest weight reduction in 
body weight (<10%) can lead to a marked reduction in intra-
hepatic lipid content, improved hepatic insulin sensitivity, and 
normalization of fasting plasma glucose concentration [7,10].
Summarizing all current available reports, it appears that 
weight loss in the range of 5% to 7% clearly decreases steatosis 
and associated metabolic parameters, but 8% to 10% weight 
reduction is needed to reverse steatohepatitis [3,7,10,14,16,18, 
19]. Although weight loss ≥7% also improves NAS, fibrosis re-
mains unchanged. The threshold of 7% weight loss is achieved 
by <50% of patients, even with intensive multidisciplinary life-
style interventions [7,11].
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LIFESTYLE MODIFICATION FOR WEIGHT 
REDUCTION
Currently, weight loss is the treatment of choice to decrease 
hepatic fat accumulation and delay the progression of inflam-
mation and fibrosis. Of the ways to achieve weight reduction, 
lifestyle modifications including a programmed diet and exer-
cise are effective and sound treatment options for all patients 
with NAFLD and NASH [5,19-21]. In addition, lifestyle modi-
fications can also improve hyperglycemia, atherogenic dyslip-
idemia, and blood pressure levels. In some studies, hepatic fat 
reductions in T2DM patients were achieved by lifestyle modi-
fication even with minimal or no weight loss, which implies 
that other factors beyond weight loss also play a role in 
NAFLD and NASH improvement [3,5,6,21]. However, diets 
with different macronutrient compositions (e.g., low fat versus 
low carbohydrate) and types of exercise protocols (e.g., aerobic 
versus resistance training) have resulted in inconsistent find-
ings among studies. Another challenge may be that different 
diets may be unacceptable because of cultural food differences 
and underlying metabolic abnormalities. For example, the 
Mediterranean diet has beneficial gluco-metabolic effects in 
those individuals with metabolic abnormalities such as T2DM, 
NAFLD, and obesity, but has not been evaluated in those of 
Asian ethnicity or with specific metabolic abnormalities.
Of the lifestyle modifications, however, weight reduction by 
dietary program or intervention remains the cornerstone for 
all patients, including T2DM patients with NAFLD and 
NASH. Numerous challenges remain in the quest to find an ef-
fective and safe dietary intervention program, although several 
trials have now prioritized patients with NAFLD. It seems that 
caloric restriction has a greater role in reducing hepatic fat ac-
cumulation than dietary macronutrient composition; this re-
duction of hepatic fat accumulation delays the progression of 
inflammation and fibrosis in patients with NAFLD [7,9-
11,14,17]. In addition, it has been established that a hypocalo-
ric diet attenuates the development and progression of T2DM 
and cardiovascular risk [7,10,18]. Comparable effects have 
been observed with equally hypocaloric low-carbohydrate ver-
sus high-carbohydrate diets [22] and low-fat versus low-carbo-
hydrate diets [23]. Haufe et al. [23] demonstrated that a pro-
longed hypocaloric diet low in carbohydrates and high in fat 
had the same beneficial effects on intrahepatic lipid accumula-
tion as a traditional low-fat hypocaloric diet.
Similar to dietary modification, the type of exercise that is 
most effective and the fitness level that is optimal for diabetes 
patients with NAFLD remain to be determined. Baseline char-
acteristics of study subjects and exercise protocols are hetero-
geneous among studies, and the amount of weight loss or 
changes in surrogate biomarkers achieved after trial interven-
tion can be inconsistent. Although it is still not clear if exercise 
improves weight loss and reduces hepatic fat reduction, exer-
cise itself has been shown to improve liver enzymes and insulin 
resistance in all diabetes patients with NAFLD and NASH 
[3,21]. A systematic review of 12 studies compared the effects 
of regular aerobic exercise and/or progressive resistance train-
ing to no exercise on changes in liver fat and/or alanine amino-
transferase (ALT) levels in adults. Exercise therapy had a bene-
ficial effect on liver fat but not ALT level with minimal or no 
weight loss [24]. For adults with T2DM, a systematic review of 
14 (11 randomized and three nonrandomized) controlled tri-
als was performed to evaluate the effect of exercise interven-
tions (duration ≥8 weeks) on glycosylated hemoglobin 
(HbA1c) and BMI. Exercise training reduced HbA1c com-
pared to the non-exercising control group (7.65% in exercisers 
vs. 8.31% in non-exercisers, P<0.001), but there was no signifi-
cant change in BMI between the two groups [25]. To deter-
mine the effect of exercise on NAFLD in T2DM subjects, a 
randomized controlled trial (RCT) compared the effects of 4 
months of either aerobic training or resistance training, and 
showed that both exercise interventions resulted in similar 
weight reduction and were equally effective at reducing liver 
triglyceride content (by about 30%) in patients with T2DM 
and NAFLD [26]. Physical activity, either aerobic or resistance 
training, should be strongly promoted for the management of 
fatty liver in T2DM subjects, and the benefits of exercise are 
not exclusively contingent upon weight loss [27]. One study of 
233,676 Koreans to determine the optimal amount of exercise 
to improve NAFLD demonstrated that moderate to vigorous 
exercise >5 times per week (lasting at least 10 minutes per ex-
ercise session) decreased the risk of development of new fatty 
liver or improved resolution of existing fatty liver as assessed 
by ultrasound (US) during 5 years of follow-up [28].
Combined dietary and exercise interventions, especially 
those performed long-term, significantly improve NAFLD. 
However, a combined diet and exercise approach does not al-
ways have a synergistic effect relative to diet alone or exercise 
alone for reasons that are unclear. One possible reason for this 
is that hepatic fat reduction is correlated with the amount of 
weight reduction. Studies that have compared a hypocaloric 
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diet versus a hypocaloric diet plus exercise have failed to show 
an improvement in liver fat content with a combined approach 
[21,29,30]. A possible explanation is that body weight reduc-
tion was similar for both interventions. A meta-analysis by Ke-
ating et al. [24] showed that combined dietary and exercise in-
tervention had no significant pooled effects size (ES) when 
compared to diet alone (ES, –0.05; 95% confidence interval 
[CI], –0.38 to 0.27; P=0.76). The long-term effects of diet-plus-
exercise versus diet alone might, however, yield different re-
sults. A systematic review of 18 studies investigated whether a 
diet-plus-exercise intervention for at least 6 months was more 
effective at promoting weight loss than a diet-only intervention 
among obese or overweight adults. This review reported that a 
combined diet-plus-exercise intervention provided greater 
long-term weight loss than a diet-only intervention [31]. Fur-
thermore, in studies lasting 2 years or longer, diet-plus-exercise 
interventions have been shown to result in significantly greater 
weight loss than diet-only interventions. However, both diet-
only and diet-plus-exercise programs are associated with par-
tial weight regain [31]. Pragmatic approaches combining di-
etary restriction and a progressive increase in aerobic exercise/
resistance training are preferable and should be individually 
tailored [31-33]. However, the long-term effects of these ap-
proaches, especially on weight regain, are currently unknown.
Even though the effects of lifestyle modification in the ab-
sence of weight loss on NAFLD and NASH are unclear, it is 
clear that lifestyle changes comprising a hypocaloric diet, exer-
cise, or both can reduce the risk of cardiovascular disease as 
well as the onset and progression of T2DM [34,35]. Clearly, 
more studies are needed to completely understand the role of 
lifestyle intervention in the treatment of NASH and to estab-
lish the best treatment strategy for patients with T2DM and 
NASH [3].
For T2DM patients with NAFLD, however, pharmacological 
treatment is more powerful than lifestyle modification for glu-
cose control. Moreover, lifestyle modification plus anti-diabet-
ic drugs are likely to have a synergistic effect on reducing the 
risk factors associated with cardiovascular risk [3] and decreas-
ing hepatic fat accumulation in these patients, thereby delaying 
the progression of inflammation and fibrosis. Therefore, all pa-
tients, especially those with T2DM, should be strongly encour-
aged to adopt both lifestyle changes and anti-diabetic medica-
tion (Fig. 1).
Fig. 1. Suggested algorithm for the management of patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes 
mellitus (T2DM). 
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PHARMACOLOGICAL TREATMENTS
Patients with prediabetes or T2DM and NAFLD have the 
highest cardiometabolic disease risk [36,37]. Because patients 
with NAFLD but without any fibrosis have an excellent prog-
nosis, pharmacological treatment should be considered in bi-
opsy-proven NASH in patients with T2DM. There are no defi-
nite pharmacological treatments for NASH in patients with 
T2DM, but many drugs have been evaluated and are under in-
vestigation (Table 1).
Anti-diabetic agents
Metformin
Metformin is an insulin sensitizer and the first line agent for 
T2DM. It has been widely tested in NAFLD because insulin re-
sistance is a major pathogenic feature of T2DM patients. Early 
Table 1. Effects of treatment in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease
Body weight Liver enzymes Hepatic steatosis NAS Fibrosis RCT/MA or SR
Lifestyle modification ↓ ↓a/↔b ↓ ↓a ↓a RCT/MA or SR
Anti-diabetic agents
   Metformin ↓ ↓ ↓ ↓/↔a,b NA RCT/MA or SR
   Thiazolidinediones
      Pioglitazone   ↑ ↓ ↓ ↓a ↓a,c RCT/MA or SR
      Lobeglitazone ↑ ↓ ↓ NA NA X
   GLP-1 RA
      Liraglutide ↓ ↓ ↓a ↔a ↓a RCT
      Exenatide ↓ ↓ ↓ NA NA X
      Lixisenatide ↓ ↓ NA NA NA X
   DPP-4 inhibitors
      Sitagliptin ↔ ↓/↔b ↓/↔b NA NA X
      Vildagliptin ↔ ↓ ↓ NA NA X
   SGLT2 inhibitors
      Dapagliflozin ↓ ↓ ↓ NA ↔c RCT
      Canagliflozin ↓ ↓ ↓ NA ↓/↔b,c X
      Empagliflozin ↓ ↓ ↓ NA NA X
      Ipragliflozin ↓ ↓ ↓ NA ↓c RCT
      Luseogliflozin ↓ ↓ ↓ NA ↔c X
Non–anti-diabetic agents
   Vitamin E ↔ ↓a ↓a ↓a NA X
   Pentoxifylline NA ↓a ↓/↔a,b ↓/↔a,b ↔a X
   Obeticholic acid ↓a ↓a NA ↓a ↓a RCT
   Elafibranor NA ↓a NA ↓a ↓a RCT
   Cenicriviroc ↔a ↔a NA ↔a ↓a RCT
   Carnitine ↔ ↓ ↓ NA NA RCT
   Saroglitazar ↔ ↓ NA NA NA X
   Orlistat ↓ ↓a ↓a ↓a ↔b,c RCT/MA or SR
Bariatric surgery ↓ ↓a ↓a ↓a ↓a RCT/MA or SR
NAS, nonalcoholic fatty liver disease activity score; RCT, randomized controlled trial; MA, meta-analysis; SR, systematic review; NA, no data 
available; X, none; GLP-1 RA, glucagon-like peptide-1 receptor agonist; DPP-4, dipeptidyl peptidase-4; SGLT2, sodium-glucose co-transporter 2.
aIt is a weak level of evidence because not all study participants have been diabetes, bMixed results, cEvaluated by non-invasive hepatic fibrosis 
markers (nonalcoholic fatty liver disease fibrosis score, fibrosis-4 [FIB-4] index).
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open-label studies with metformin suggested a histologic ben-
efit [38,39], but recent RCTs have yielded negative results 
[20,40]. Furthermore, two meta-analyses found that metfor-
min did not improve liver histology in patients with NAFLD 
and NASH [41,42]. Because there is scarce evidence of the effi-
cacy of metformin in patients with NAFLD and T2DM, met-
formin is not recommended for treating NAFLD in patients 
with T2DM.
Thiazolidinediones
Pioglitazone
Pioglitazone is a peroxisome proliferator-activated receptor 
(PPAR)-γ agonist with insulin-sensitizing effects and belongs 
to a class of drugs known as thiazolidinediones (TZDs). Piogli-
tazone has a lot of evidences for the treatment of NASH in pa-
tients with T2DM and has been shown to improve liver histol-
ogy. In one RCT, 55 patients with impaired glucose tolerance 
or T2DM (mean HbA1c 6.2%) and liver biopsy-confirmed 
NASH were randomly assigned to 6 months of treatment with 
a hypocaloric diet plus pioglitazone (45 mg daily) or a hypoca-
loric diet and placebo. Pioglitazone improved insulin sensitivi-
ty and aminotransferase, steatosis (P=0.003), ballooning ne-
crosis (P=0.02), and inflammation (P=0.008) [43]. Another 
RCT evaluated the efficacy and safety of long-term piogli-
tazone treatment in patients (n=101) with biopsy-proven 
NASH and prediabetes or T2DM (n=52). All patients were 
prescribed a hypocaloric diet (500 kcal/day deficit from 
weight-maintaining caloric intake) and were then randomly 
assigned to pioglitazone (45 mg/day) or placebo for 18 months, 
followed by an 18-month open-label phase of pioglitazone 
treatment. Among patients randomly assigned to pioglitazone, 
58% achieved the primary outcome (a reduction of at least 2 
points in NAS in two histologic categories without worsening 
of fibrosis) and 51% had resolution of NASH (P<0.001 for 
each). Pioglitazone treatment was also associated with an im-
provement in histologic score (P=0.039). All 18- month meta-
bolic and histologic improvements persisted over 36 months of 
therapy [44]. In addition, pioglitazone reduced liver fibrosis 
and increased adipose tissue insulin sensitivity to a significant-
ly greater extent in patients with T2DM than in patients with 
prediabetes [45]. In the case of advanced fibrosis (stage F3–
F4), meta-analysis showed that pioglitazone use improved fi-
brosis in patients with NASH and T2DM, even in patients 
without diabetes [46]. Weight gain, fluid retention, and bone 
loss are common side effects of pioglitazone treatment, so risks 
and benefits should be considered before starting therapy. Pio-
glitazone could be a first line therapy for patients with NASH 
and T2DM, similar to metformin for the initial treatment of 
patients with T2DM. However, more data are required before 
pioglitazone is routinely used to treat NAFLD in patients with 
T2DM.
Lobeglitazone
Lobeglitazone is a novel TZD and is currently being prescribed 
for T2DM in Korea. Lobeglitazone improved hepatic steatosis 
in an animal model, similar to what has been observed for oth-
er TZDs [47]. In a multicenter, prospective, open-label, explor-
atory clinical trial, lobeglitazone treatment (0.5 mg daily) for 
24 weeks improved liver enzymes and ameliorated hepatic fat 
content as assessed by transient liver elastography with con-
trolled attenuation parameter (CAP) in 43 patients with 
T2DM and NAFLD [48].
Glucagon-like peptide-1 receptor agonists
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are ap-
pealing candidates for the treatment of NAFLD and NASH be-
cause they can reduce weight and enhance insulin action. 
However, GLP-1 RA is not currently recommended for the 
treatment of NAFLD in patients with T2DM because of limit-
ed data.
Liraglutide
The Liraglutide Effect and Action in Diabetes (LEAD) pro-
gram performed individual patient data meta-analysis using 
six 26-week, phase III, randomized controlled T2DM trials. 
Twenty-six weeks of treatment with liraglutide 1.8 mg reduced 
liver enzymes in patients with T2DM (liraglutide –8.20 IU/L 
vs. placebo –5.01 IU/L, P=0.003). This effect was likely medi-
ated by liraglutide’s weight loss and glycemic control effects 
[49]. In the Liraglutide Efficacy and Action in NASH (LEAN) 
study, which was a randomized, placebo-controlled trial con-
sisting of 52 patients with biopsy-proven NASH, liraglutide 
(1.8 mg daily) for 48 weeks was associated with greater resolu-
tion of steatohepatitis and less progression of fibrosis. Among 
the LEAN study population, 32.7% of participants were pa-
tients with T2DM [50]. Larger studies with liraglutide are 
needed to confirm its effects on NASH in patients with T2DM.
Exenatide
No study has investigated exenatide treatment of NASH in 
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patients with T2DM, but one study investigated its effects on 
NAFLD. The investigators treated 60 newly diagnosed patients 
with obesity, NAFLD with elevated liver enzymes, and T2DM 
with exenatide plus insulin glargine or insulin aspart plus insu-
lin glargine. Levels of ALT, aspartate aminotransferase (AST), 
and γ-glutamyl transpeptidase (γ-GTP) in the exenatide group 
were significantly lower than in the intensive insulin group 
(P<0.001), and the reversal rate of fatty liver was significantly 
higher in the exenatide group (93.3% vs. 66.7%, respectively; 
P<0.01) [51].
Lixisenatide
The results of 12 RCTs on lixisenatide versus placebo and three 
RCTs with active comparators were analyzed by meta-analysis 
to evaluate the effects of lixisenatide on elevated liver enzyme 
levels in patients with T2DM. Lixisenatide increased the pro-
portion of patients with normalization of ALT compared with 
placebo or active comparators [52].
Dipeptidyl peptidase-4 inhibitors
Dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used 
in patients with T2DM, but there are few studies of the efficacy 
of DPP-4 inhibitors in patients with T2DM and NAFLD. These 
inhibitors are not believed to have a beneficial effect on NAFLD.
Sitagliptin
Results for sitagliptin have been mixed. Significant decreases 
in plasma glucose and serum HbA1c, AST, ALT, and γ-GTP 
levels were reported after 4 months of treatment of NAFLD 
patients with T2DM with sitagliptin [53]. A pilot clinical study 
demonstrated that sitagliptin could improve hepatocyte bal-
looning and liver enzymes in patients with T2DM and NASH 
after 1 year of treatment [54]. However, many other studies 
have failed to show an effect of sitagliptin treatment on liver fat 
content [55,56], liver enzyme levels [57], or liver stiffness [56].
Vildagliptin
One study has investigated the efficacy of vildagliptin in pa-
tients with T2DM and NAFLD. In patients with T2DM and 
hepatic steatosis, mean fasting liver triglyceride content de-
creased by 27% with vildagliptin, from 7.3%±1.0% (baseline) 
to 5.3%±0.9% (endpoint) during 6 months of therapy, and this 
was unrelated to changes in body weight. Additionally, ALT fell 
from 27.2 to 20.3 IU/L in the vildagliptin group (P=0.007) [58].
Sodium-glucose co-transporter 2 inhibitors
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are in-
creasingly been used to treat T2DM and they promote weight 
loss, which is an attractive property for the treatment of pa-
tients with NAFLD. Although SGLT2 inhibitors are not yet 
generally recommended for the treatment of NAFLD in pa-
tients with T2DM, studies reporting beneficial effects are accu-
mulating.
Dapagliflozin
In a retrospective study comparing dapagliflozin and DPP-4 
inhibitors, dapagliflozin treatment resulted in liver enzyme 
improvement in patients with T2DM and NAFLD [59]. Many 
small studies have reported that dapagliflozin treatment had 
beneficial effects on levels of liver enzymes, liver fat content, 
and/or liver stiffness in patients with T2DM and NAFLD [60-
62]. In a randomized, active-controlled, open-label trial, dapa-
gliflozin significantly decreased CAP (314 to 290 dB/m; P= 
0.0424) and tended to decrease liver stiffness measurements in 
57 patients with T2DMM and NAFLD [60]. The Effects of 
Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat 
Content in Diabetic Patients (EFFECT-II) study, which was a 
randomized, placebo-controlled, double-blind, parallel-group 
study, showed that combined treatment with dapagliflozin and 
omega-3 carboxylic acids significantly reduced liver fat content 
as assessed by magnetic resonance imaging (MRI)-derived 
proton density fat fraction (PDFF). In addition, dapagliflozin 
monotherapy reduced all measured hepatocyte injury markers 
in patients with T2DM and NAFLD [61]. Another prospective, 
randomized, active-controlled, single center study in 55 Japa-
nese T2DM patients showed that dapagliflozin treatment for 6 
months significantly reduced liver fat accumulation as assessed 
by the liver-to-spleen (L/S) attenuation ratio using abdominal 
computed tomography (CT) compared with non-SGLT2 in-
hibitor treatment [62].
Canagliflozin
Pooled data from four 26-week and two 52-week phase III 
clinical trials of canagliflozin showed significant reductions in 
ALT, AST, γ-GTP, and alkaline phosphatase compared with 
placebo in patients with T2DM [63]. These protective effects of 
canagliflozin were also found in a meta-analysis of data ex-
tracted from RCTs [64]. In a small (n=20), prospective, non-
randomized, open-label single-arm study, canagliflozin (100 
mg daily) treatment for 12 months significantly reduced he-
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patic fat fraction (17.6% to 12.1%; P<0.005) as measured by 
MRI in patients with T2DM and NAFLD [65]. Fibrosis-4 (FIB-
4) index values decreased after 6 months of treatment with 
canagliflozin (100 mg daily) in 35 patients with T2DM and 
NAFLD [66].
Empagliflozin
In the Empagliflozin Cardiovascular Outcome Event Trial in 
Type 2 Diabetes Mellitus (EMPA-REG OUTCOME) trial, em-
pagliflozin reduced aminotransferase levels (ALT>AST) in 
patients with T2DM [67]. The Effect of Empagliflozin on Liver 
Fat Content in Patients With Type 2 Diabetes (E-LIFT) trial, 
which was an investigator-initiated, prospective, open-label, 
randomized clinical study, showed that empagliflozin (10 mg 
daily) significantly reduced liver fat (16.2% to 11.3%; P< 
0.0001) as measured by MRI-PDFF in 50 patients with T2DM 
and NAFLD [68].
Ipragliflozin
Ipragliflozin treatment for 24 weeks (50 mg daily) reduced liv-
er enzymes in 43 patients with T2DM and NAFLD and tended 
to decrease liver stiffness as measured by transient elastogra-
phy [69]. Subgroup analysis of data from the Specified drug 
use resulTs survEy of lpragLifLozin treAtment in type 2 diabe-
tes patients: LONG-TERM use (STELLA-LONG TERM), an 
ongoing 3-year post-marketing surveillance study on the long-
term efficacy and safety of ipragliflozin, showed that fatty liver 
index (FLI) decreased (63.2677 to 56.7137; P<0.05) and liver 
function improved in patients with T2DM [70]. Interestingly, 
in this open-label, randomized, active-controlled trial, the effi-
cacy of ipragliflozin was compared to that of pioglitazone in 66 
patients with T2DM and NAFLD. At week 24, the mean L/S 
ratio on CT had increased by 0.22 in the ipragliflozin group 
and 0.21 in the pioglitazone group (P=0.90), and both im-
provements were significant. The FIB-4 index decreased sig-
nificantly by 0.22 in the ipragliflozin group [71].
Luseogliflozin
In a single-center, prospective, randomized, open-label, con-
trolled study, luseogliflozin treatment (2.5 mg daily) for 6 
months reduced liver fat deposition (L/S ratio on CT 0.907 to 
1.033; P=0.0008) in 32 patients with T2DM and NAFLD [72]. 
A prospective, single-arm trial showed that luseogliflozin 
treatment (2.5 mg daily) for 24 weeks reduced hepatic fat con-
tent as evaluated by MRI in patients with T2DM and NAFLD, 
but hepatic fibrosis markers did not change [73].
Non–anti-diabetic agents
Vitamin E
Vitamin E is an antioxidant that prevents liver injury by block-
ing intrinsic apoptotic pathways and protecting against oxida-
tive stress [9,74]. Vitamin E improves liver histology in nondi-
abetic adults with biopsy-proven NASH [74], but is not recom-
mended in patients with diabetes because of lack of evidence 
[6]. In addition, there are some concerns that long-term use of 
vitamin E may be associated with increased all-cause mortality, 
increased incidence of hemorrhagic stroke, and increased risk 
of prostate cancer [6,75,76].
Lipid-lowering agents
Although ezetimibe and omega-3 polyunsaturated fatty acids 
have been shown to have a beneficial effect on NASH in ani-
mal studies, lipid-lowering agents such as statins, ezetimibe, fi-
brates, niacin, omega-3 polyunsaturated fatty acids, and cole-
sevelam do not improve hepatic steatosis in patients with 
NAFLD [6,77-81]. There is also no evidence that these agents 
are effective treatment options in patients with T2DM and 
NAFLD.
Ursodeoxycholic acid
Ursodeoxycholic acid (UDCA), a naturally occurring bile acid, 
reduces oxidative stress and has antiapoptotic properties 
[82,83]. Several studies have reported that UDCA improved 
liver enzymes and hepatic steatosis in patients with NAFLD 
[84,85]. This bile acid was expected to be effective in treating 
NASH, but both conventional (13 to 15 mg/kg daily) and high 
(23 to 28/kg daily) doses of UDCA failed to result in histologic 
improvements in patients with NASH [86,87].
Pentoxifylline
Pentoxifylline inhibited a number of pro-inflammatory cyto-
kines including tumor necrosis factor-α, and had a beneficial 
effect on NASH in an animal study [88]. Pentoxifylline (400 
mg three times a day) improved the histological features of 
NASH in 55 adults with biopsy-confirmed NASH, but only 
9.1% of participants had T2DM [89]. Another study reported 
no histological improvement in 30 patients, so larger studies 
are needed to establish its potential utility in patients with 
NASH and T2DM [90].
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Obeticholic acid
Obeticholic acid is a natural agonist of the farnesoid X receptor 
and has been shown to decrease insulin resistance and hepatic 
steatosis in an animal model [91]. In a double-blind, placebo-
controlled, proof-of-concept study, obeticholic acid treatment 
for 6 weeks improved insulin resistance and reduced markers 
of liver inflammation and fibrosis in patients with T2DM and 
NAFLD [92]. The Farnesoid X Receptor Ligand Obeticholic 
Acid in NASH Treatment (FLINT) trial, which was a multi-
center, randomized, placebo-controlled trial, showed that 
obeticholic acid (25 mg daily) treatment for 72 weeks im-
proved liver histology in patients with NASH. Among the 
FLINT trial participants, 52.7% had T2DM. Main concerns as-
sociated with obeticholic acid treatment are increased low 
density lipoprotein cholesterol and pruritus [33,93]. Further 
studies are needed to clarify the long-term benefits and safety 
of obeticholic acid in patients with T2DM and NAFLD.
Elafibranor
Elafibranor is a dual agonist of PPAR-α and PPAR-δ and im-
proves insulin resistance in liver and peripheral tissue [94]. In 
a phase IIb international, randomized, double-blind placebo-
controlled trial, elafibranor treatment (120 mg daily) for 52 
weeks tended to induce resolution of NASH without fibrosis 
worsening despite some methodological limitations. The pre-
defined end point was not met in the intention to treat popula-
tion and 39.1% of study participants had T2DM [95]. A phase 
III trial (The Efficacy and Safety of Elafibranor Versus Placebo 
in Patients with Nonalcoholic Steatohepatitis [RESOLVE-IT]) 
is currently underway to evaluate the ability of elafibranor to 
achieve resolution of NASH without worsening fibrosis.
Cenicriviroc 
Cenicriviroc, a dual antagonist of C-C chemokine receptors 
type 2 and 5 (CCR2/CCR5), was shown to have potent anti-in-
flammatory and antifibrotic activity in an animal model [96]. 
In the Efficacy and Safety Study of Cenicriviroc for the treat-
ment of Nonalcoholic Steatohepatitis in Adult Subjects with 
Liver Fibrosis (CENTAUR) study, which was a randomized, 
double-blind, multinational phase IIb study, cenicriviroc treat-
ment (150 mg daily) for 1 year resulted in improvement in fi-
brosis and no worsening of steatohepatitis compared with pla-
cebo [97]. In that study, half of the participants had T2DM and 
two-thirds had metabolic syndrome. 
Carnitine
Carnitine is a modulator of mitochondrial free fatty acid trans-
port and oxidation and has anti-oxidative activity in hepato-
cytes [98]. In patients with NASH, L-carnitine treatment (1 g 
daily) for 24 weeks improved liver enzymes and histological 
manifestations [99]. In the Carnitine-OROtate in NAFLD pa-
tients with diabetes (CORONA) trial, which was a random-
ized, controlled, double-blind trial, treatment with carnitine-
orotate complex (824 mg three times daily) for 12 weeks im-
proved serum ALT and appeared to improve hepatic steatosis 
as assessed by CT in 78 patients with T2DM and NAFLD 
[100].
Saroglitazar
Saroglitazar is a dual PPAR-α/γ agonist that has been approved 
in India for the treatment of dyslipidemia in patients with dia-
betes. In a 16-week prospective, multicenter, randomized, 
double-blind, placebo-controlled, three-arm phase III study in 
subjects with hypertriglyceridemia (>200 and <500 mg/dL) 
and T2DM, saroglitazar reduced alkaline phosphatase as well 
as triglyceride levels [101]. No study has investigated the effect 
on saroglitazar in patients with NASH, although saroglitazar 
improved NASH in an animal model [102]. 
Anti-obesity drugs
Because weight reduction is a key component of the treatment 
of NAFLD, anti-obesity drugs are potential pharmacological 
candidates. However, few studies have investigated the efficacy 
of anti-obesity drugs on the treatment of NAFLD, with the ex-
ception of orlistat [103].
Orlistat
Orlistat inhibits fat absorption and has been approved as an 
anti-obesity drug. In a randomized, double-blind, placebo-
controlled study of 52 patients with NAFLD as diagnosed by 
US and confirmed by liver biopsy, orlistat (120 mg three times 
daily for 6 months) improved serum ALT level (48.0% vs. 
26.4%) and steatosis on US in NAFLD patients beyond its ef-
fect on weight reduction. Among the study participants, 21% 
had T2DM [104]. Another study evaluated the effect of orlistat 
on NAFLD in patients who received a 1,400 kcal/day diet plus 
vitamin E (800 IU) daily. Orlistat (120 mg three times a day) 
did not enhance weight loss or improve liver enzymes and his-
topathology in 50 overweight subjects (10% of subjects had 
been T2DM). However, subjects who lost ≥5% of body weight 
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over 9 months showed improved insulin resistance and steato-
sis, and those subjects who lost ≥9% also achieved improve-
ment in liver histology and NAS [105]. In a meta-analysis, orli-
stat improved liver enzymes but not liver fibrosis score (P= 
0.71) in patients with NAFLD [106]. 
Lorcaserin
Lorcaserin is a serotonin 2c receptor agonist that promotes 
weight loss while improving T2DM. One study has evaluated 
the effect of lorcaserin on cardiometabolic parameters. In a 
6-month-long, randomized (1:1), placebo-controlled, double-
blinded clinical trial, lorcaserin reduced FLI (P<0.001) in 48 
obese subjects without T2DM [107]. Further studies are need-
ed to determine if lorcaserin is effective for the treatment of 
NAFLD in patients with T2DM.
Drugs under investigation
The therapeutic landscape for NAFLD/NASH is evolving rap-
idly, with many drugs currently being assessed in clinical trials. 
Among them, some drugs have being evaluated in patients 
with NAFLD and T2DM (Table 2).
BARIATRIC SURGERY
In severely obese patients, bariatric surgery is accepted as the 
primary treatment modality for sustained weight loss and ef-
fective improvement or resolution of obesity-related metabolic 
complications. In a large cohort study, bariatric surgery im-
proved survival and reduced the incidence of death from car-
diovascular disease and malignancy, the two most common 
causes of death in patients with NAFLD.
Mathurin et al. [108] prospectively correlated clinical and 
metabolic data with liver histology before surgery and at 1 and 
5 years after surgery in 381 adult patients with severe obesity. 
Most histologic benefits were evident at 1 year, with no differ-
ences in liver histology between 1 and 5 years following bariat-
ric surgery [108]. Lassailly et al. [109] prospectively examined 
109 patients with NASH at the time of bariatric surgery and 
performed follow-up biopsies 1 year later. Eighty-five percent 
of patients had NASH resolution (95% CI, 75.8 to 92.2). Im-
portantly, in contrast to past data, fibrosis improved at 1 year 
after surgery in 33% of patients. Among the study participants, 
63.3% had T2DM [109]. A meta-analysis of available data in 
2015 also showed that the majority of patients who underwent 
bariatric surgery had improvement or complete resolution of 
the histopathological features of steatosis, inflammation, and 
ballooning. Fibrosis also improved, as evidenced by a weighted 
mean decrease of 11.9% in the incidence of fibrosis [110]. A 
recent meta-analysis of 32 cohort studies including 3,093 biop-
sies reported consistent findings. Bariatric surgery resulted in 
biopsy-confirmed resolution of steatosis in 66% of patients 
(95% CI, 56% to 75%), inflammation in 50% (95% CI, 35% to 
64%), ballooning degeneration in 76% (95% CI, 64% to 86%), 
and fibrosis in 40% (95% CI, 29% to 51%). Mean NAS also de-
creased significantly after bariatric surgery (mean difference, 
2.39; 95% CI, 1.58 to 3.20; P<0.001) [111].
With regard to procedure selection, there is no reliable data 
favoring sleeve gastrectomy over Roux-en-Y gastric bypass or 
vice versa. However, considering the safety of surgery itself, 
sleeve gastrectomy is recommended in patients with NASH 
cirrhosis [112,113].
Although no studies have reported the use of bariatric sur-
gery to treat NAFLD/NASH in Korea, NAFLD/NASH is in-
cluded in the clinical practice guidelines for performing bariat-
Table 2. Pharmacological agents currently under investigation for the treatment of nonalcoholic fatty liver disease in patients with 
diabetes
Drug Mechanism of action Latest phase of development
Dulaglutide GLP-1 RA Phase IV recruiting
Tofogliflozin SGLT2 inhibitor Phase IV recruiting
Lanifibranor (IVA337) PPAR α/γ/δ triple activators Phase II recruiting
BKFB8488A Antibody to fibroblast growth factor-1 complex Phase I recruiting
SAR425899 Dual GLP-1 receptor/glucagon receptor agonist Phase II anticipated
HTD1801 Lipid modulator Phase II recruiting
Foralumab Oral anti-CD3 antibody Phase II anticipated
GLP-1 RA, glucagon-like peptide-1 receptor agonist; SGLT2, sodium-glucose co-transporter 2; PPAR, peroxisome proliferator-activated receptor.
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ric surgery, which include BMI >35 kg/m2 or BMI >30 kg/m2 
plus obesity-related comorbidities. 
CONCLUSIONS
Despite many advances in the treatment of NAFLD, the only 
approved option for NAFLD in patients with T2DM is weight 
loss. However, it is not easy to maintain weight loss and T2DM 
itself confers high cardiovascular risk. Therefore, lifestyle inter-
vention supported by pharmacological treatment is necessary 
in patients with T2DM and NAFLD. Although many drugs 
have been investigated, pioglitazone is currently the best first-
line therapy in patients with T2DM and NAFLD. As new 
agents become available, combination strategies will likely be 
used to treat NAFLD, similar to how T2DM is currently treat-
ed. Much progress has been made in the understanding, diag-
nosis, and treatment of NAFLD over the past few decades. In 
the future, we expect early intervention and individualized 
treatment for NAFLD to become standard for all patients with 
T2DM. 
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